The Thesis
PanicFade v4 bets on a well-documented behavioural edge: markets overreact to bad news, and prices tend to revert toward fundamentals afterward. The strategy buys names hit by a sentiment shock (sentiment below -0.4) that are already technically oversold — RSI14 under 35 and trading below their 20-day moving average — then sizes into the panic. It exits on reversion (RSI14 back above 50 or price reclaiming the SMA20) and hard-stops on fresh lows under continued negativity, treating that as a genuine fundamental break rather than noise.
Crucially, the universe is 24 mega-cap, liquid names (AAPL, JPM, WMT, XOM and peers). Fading panic in blue chips is a materially safer expression of the idea than doing it in small caps, where a headline shock is more often the start of a real repricing.
Recent Activity
The live paper account has been quiet. Across the last six scheduled runs (10–17 September), only one produced a fill: a buy of 21 shares of BAC at $59.86 on 15 September, following an earlier position in WMT (10 shares at $103.12) on 28 August. Most days report 0 executed, 0 rejected. That inactivity is a feature, not a bug — the entry filter is deliberately strict, so the strategy spends most of its time waiting for a qualifying setup.
That said, the live equity tells a sober story: total value sits at $9,984.91 against a nominal $10k start, with $7,696 still in cash. Live results so far are essentially flat-to-slightly-negative — a reminder that a strong backtest is a hypothesis, not a receipt.
Backtest and Validation
On paper the record is strong. Over 1,233 days the strategy returned 37.93% (6.79% CAGR), with a 62.88% win rate, a contained 9.3% max drawdown, and a Sharpe of 0.96 across 530 trades.
The validation is where PanicFade earns real credibility. All four walk-forward folds were positive, and — notably — performance improved monotonically across them (1.6% → 3.88% → 10.14% → 21.7%), with the final out-of-sample fold posting a 2.44 Sharpe. The Probabilistic Sharpe Ratio of 0.985 is excellent.
The Risks
Balance demands scrutiny of the same numbers. The Deflated Sharpe Ratio is just 0.56 — once you penalise for the 27 trials run during development, confidence in a genuine edge drops from "near-certain" to "more likely than not." The fold-by-fold Sharpe also swings wildly (0.19 to 2.44), which reads as regime dependence: the strong recent fold may flatter a strategy that struggles in trending, low-panic markets.
Other cautions: turnover is high (5,807%), so real-world fees and slippage will bite harder than the backtest's flat cost assumption; the sample of true panic events is inherently thin; and the flat live equity so far offers no confirmation yet.
Verdict
A disciplined, literature-grounded strategy with genuinely clean validation — but one whose edge is modest after deflation and whose live track record is still a blank page. Worth watching; not yet worth conviction.